Heron Therapeutics Inc. said underwriters in its common stock offering fully exercised their option to purchase an additional 1,845,000 common shares.

Total net proceeds, minus expenses and underwriting discounts and commissions, are now expected to total about $163.7 million.

The sale of the additional shares is expected to close Feb. 3.

BofA Merrill Lynch, Cowen and Co. LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. and JMP Securities LLC are acting as lead managers while Noble Capital Markets, LifeSci Capital, Aegis Capital Corp. and Lake Street Capital Markets are acting as co-managers for the offering.